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We aimed to describe, for the first time, the prescribing patterns among patients on 
persistent respiratory treatment, from the Portuguese electronic prescription and 
dispensing database. 
This was a one-year retrospective population-based analysis of prescriptions 
(n=39810) for medication for respiratory disease and exacerbations. Cluster analysis 
was applied based on medication and prescribers’ specialty. 
Prescribing patterns were grouped and labelled as: possible medication for asthma 
and allergic rhinitis (General Practitioners-GPs and allergists to younger patients); 
COPD (GPs and pulmonologists to older patients); asthma or Asthma-COPD 
Overlap (GPs and pulmonologists); exacerbation, infection and relievers. 
This analysis was an important first step to understand the Portuguese reality on the 
treatment of respiratory diseases. 
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ACO -Asthma-COPD Overlap 
Anti-H1 -H1-antihistamine 
ARIA -Allergic Rhinitis and its Impact on Asthma 
BDNP -Portuguese electronic prescription and dispensing database (Base de Dados 
Nacional de Prescrições) 
COPD -Chronic Obstructive Pulmonary Disease 
GINA -Global Initiative for Asthma 
GPs -General Practiotioners 
ICS -Inhaled corticosteroids 
IgE -Immunoglobulin E 
LABA -Long-Acting Beta2-Agonists 
LAMA -Long-Acting Muscarinic Antagonists 
LTRA -Leukotriene Receptor Antagonists 
nCS -nasal corticosteroids 
OCS -Oral corticosteroids 
OTC – Over-the-counter 
PRT -Persistent Respiratory Treatment 
RWD -Real World Data 
SABA -Short-Acting Beta2-Agonists 
SAMA -Short-Acting Muscarinic Antagonists 
95%CI – 95% Confidence Interval 
P25-P75 -Percentiles 25- 75 
Introduction 
The goals of asthma and chronic obstructive pulmonary disease (COPD) 
management are to reduce symptoms and minimize the risk of future exacerbations, 
obtained by continuous assessment, treatment, and review of the patient’s response 
(1,2). Asthma and COPD are heterogeneous diseases with similarities in symptoms 
and management options, moreover, some patients present an overlap of asthma 
and COPD features (asthma-COPD overlap - ACO). Although the use of the term 
ACO is controversial and both its concept and terminology are not robust, it is useful 



















Real-world data (RWD) routinely collected in the course of healthcare delivery (3) 
have an important role in acknowledging the use and effects of treatments, and the 
overall heterogeneity of chronic diseases (4). RWD has also been used to describe 
medication prescribing for asthma and DPOC (5–7). 
For the analysis of RWD, the unsupervised statistical techniques are increasingly 
popular approaches to identify and reveal new insights among healthcare data (8). 
They aim to reveal possible natural clusters grouped by similar characteristics, 
otherwise not be apparent, in other words, not defined a priori. Each cluster should 
be as homogenous as possible and have minimal overlapping to the other clusters. 
Common clustering methods are hierarchical, partitional and two-step (distance-
based methods) and latent class analysis (model-based methods) (9). Unsupervised 
clustering methods have been used to reveal phenotypes of asthma (10,11), COPD 
(12) and allergic diseases (13,14), and to identify factors of increased healthcare 
utilization (15) and prescription patterns (16). 
In Portugal the research based on RWD, namely based on the national electronic 
prescription database is scarce. Recently we reported an analysis of data from the 
Portuguese electronic prescription and dispensing database that showed an 
association between insufficient prescription of maintenance medication and over-
prescription of short-acting beta2 agonists (SABA) and oral corticosteroids (OCS) 
(17). Further research on maintenance prescription patterns may contribute to a 
better understanding of the underlying challenges of the management of chronic 
respiratory diseases in “real-world” healthcare. 
Aims 
We aim to describe medication patterns in the Portuguese electronic prescription 
and dispensing database (BDNP), among patients over 15 years old with persistent 
respiratory treatment (PRT). 
Methods 
Study design 
This study was a retrospective population-based analysis of a random sample of 




















The BDNP records data of all the prescriptions and respective dispensing in 
mainland Portugal. The population of interest in this study consists of patients to 
whom medication for respiratory and/or allergic diseases and exacerbations was 
prescribed at least once, between January 2016 and December 2016. We obtained 
all the prescriptions from a random sample of 2% (n=103 647) of these patients, 
corresponding to 1 129 512 prescriptions (Figure 1). A more detailed description of 
the data source has been previously published (17). 
Participants 
In this study, we analysed the prescriptions (n=248 045) between January 2016 and 
December 2016 for medications for respiratory and/or allergic diseases and 
exacerbations (Table 1), from a sample of patients from mainland Portugal, aged 15 
years and above (Figure 1). We analysed the prescriptions delivered to patients on 
persistent respiratory treatment (n=8 798, Figure 1) and we considered different 
prescriptions ordered by the same prescriber, for the same patient, on the same day, 
as a unique prescription (n=39 810, Figure 1). 
Variables 
Persistent respiratory treatment (PRT) was defined as having prescriptions for more 
than 2 packages of any of the six classes of respiratory maintenance medications: 
inhaled corticosteroids (ICS) alone or in fixed-dose combination with long-acting 
beta2 agonists (LABA); leukotriene receptors antagonists (LTRA); long-acting 
muscarinic antagonist (LAMA) alone or in a fixed-dose combination with LABA or 
LABA alone. 
Medication type – active substances were classified in 14 medication types 
according to the International Non-proprietary Names: ICS plus LABA (ICS+LABA); 
LTRA; ICS alone; LABA alone; SABA alone; LAMA alone; LABA plus LAMA 
(LABA+LAMA); Xanthine; (short-acting muscarinic antagonists (SAMA) alone; SABA 
plus SAMA (SABA+SAMA). For a better understanding of the clinical sense of the 
clusters, we additionally included Antibiotics; OCS; H1-antihistamine (Anti-H1); nasal 
corticosteroids (nCS) and Expectorants combined or not with Cough suppressants in 
the analysis. Prescribers’ Specialties – the specialties (n=52) were grouped in 
general practitioners (GPs), pulmonologists, allergists, internists, and the other, less 

















Packages – number of packages of each medication type prescribed. In the BDNP 
system, it is possible to include several packages for each medication in the same 
prescription. 
Additional external variables were analysed, such as the age of the patient; region of 
the prescription (mainland Portugal has 5 NUTS II regions that were recoded in 3 - 
North, Center and South (Lisbon, Algarve and Alentejo); Healthcare unit (primary 
care, secondary care or other) and healthcare provider (public or private). 
Cluster analysis 
Cluster analysis techniques were applied to identify prescription patterns based on 
medication and specialty of the prescriber using a two-step approach. The variables 
included in the final model were medication type (ICS+LABA; LTRA; ICS alone; 
LABA alone; SABA alone; LAMA alone; LABA+LAMA; Xanthine; SAMA alone; 
SABA+SAMA); and the specialty of the prescribers (GPs; pulmonologists; allergists; 
internist; other). In the first step, an automatic clustering algorithm estimated the 
number of clusters that best fitted the data, based on the Bayesian Information 
Criterion. This estimate was then used for the clustering analysis based on log-
likelihood distance measures (18). We selected the parameters for which the model 
had the highest quality and the final model had a silhouette coefficient of 0.5. The 
presence of additional medication (Antibiotics, OCS, anti-H1, nCS and expectorants 
combined or not with cough suppressants) was explored for each cluster. 
Statistical methods 
Categorical variables are presented as absolute frequencies and proportions and 
95% Confidence Interval for proportion (95%CI). Age differences between clusters 
were tested by Kruskal-Wallis chi-square. Statistical significance was set for a p-
value of less than 0.05. 
IBM SPSS Statistics 25 was used to conduct the two-step cluster analysis and 
RStudio 1.1.456 (https://rstudio.com/) for pre-processing and other analyses. 
Results 
A total of 39 810 prescriptions of PRT (Figure1) were registered in 2016 for the 
analysed sample, corresponding to 312 527 packages (Table 1). Maintenance 


















and LTRA (6.7%). Globally, the most prescribed drugs were H1-antihistamines 
(23.5%) and antibiotics (17.9%).  
The cluster analysis conducted to assess prescription patterns based on medication 
and specialty of the prescriber, revealed that an eleven-cluster model was the 
solution that best fitted our data. The characteristics of prescriptions and external 
variables are described in Table 2. The most frequent prescription patterns are 
grouped in clusters 10 and 5, prescribed exclusively by GPs, and in clusters 7 and 
11, written by prescribers with different specialties. The clusters’ characteristics are 
summarized in Figure 2 and Table S1 (Supplementary material). Additional 
medication (Antibiotics, OCS, anti-H1, nCS and expectorants combined or not with 
cough suppressants) and patients’ age are also presented for each cluster. 
Regarding external variables (Table 2), Cluster 8 was the pattern prescribed to 
youngest patients (p<0.001) and clusters 1 and 4 to the oldest (p<0.001). At primary 
care units and public healthcare providers, the most frequent prescriptions are 
grouped in Cluster 5 or 10, whereas secondary healthcare services and private 
providers prescriptions are grouped in cluster 11 more often. 
Based on the clinical interpretation of the medication in each cluster, including 
patients’ age, they were grouped into four subsets, as follows: 
Medication for possibly Allergic Rhinitis and Asthma 
Clusters 6: prescriptions for LTRA alone or combined mostly with ICS+LABA. 
Additional frequent medications were anti-H1 and nCS. Prescribed GPs for 
patients with a median age of 63 years old. 
Cluster8: prescriptions for LTRA alone or combined mostly with ICS+LABA. 
Additional frequent medications were anti-H1 and nCS. Prescribed by allergists 
for patients with a median age 44 years old.  
Medication for possibly Asthma or ACO 
Clusters 5: prescriptions for ICS+LABA fixed combination, prescribed 
exclusively by GPs for patients with a median age of 68 years old.  
Cluster 7: prescriptions for ICS, LABA and LAMA. Prescribed mostly by GPs 

















Cluster 2: prescriptions for ICS+LABA alone or combined with LTRA, and 
additionally includes prescriptions for anti-H1 and nCS. Prescribed mostly by 
pulmonologists for patients with a median age of 63 years old.  
Cluster 4: prescriptions for ICS+LABA, Xanthines, LAMA and LTRA. 
Prescribed mostly by GPs for patients with a median age of 75 years old. 
Medication for possibly COPD 
Cluster 1: prescriptions for LAMA alone or combined with ICS+LABA. Prescribed 
mostly by GPs for patients with a median age of 74 years old. 
Cluster 9: prescriptions for LABA+LAMA alone or combined with ICS. Prescribed 
mostly by GPs and pulmonologists for patients with a median age of 72 years old. 
Medication for infection, exacerbation and relievers of symptoms 
Cluster 10: prescriptions for antibiotics, OCS, anti-H1, nCS and expectorants with 
cough suppressants, with no maintenance treatment. Prescribed exclusively by GPs 
for patients with a median age of 63 years old. 
Cluster 11: prescriptions for antibiotics, OCS, anti-H1, nCS and expectorants with 
cough suppressants, with no maintenance treatment. Prescribed mostly by 
specialties not related to respiratory diseases for patients with a median age of 66 
years old. 
Cluster 3: prescription mainly for SABA, SAMA, but also with ICS+LABA, ICS, LTRA 
and LAMA. Prescribed mostly by GPs for patients with a median age of 66 years old. 
Discussion 
Eleven different prescriptions patterns clusters were revealed by unsupervised 
analysis based on medications and prescribers’ specialties, and these clusters were 
grouped in four, based on the theoretical therapeutic indications of the medications 
and patient’s age in each cluster. 
Comparing the clusters obtained by unsupervised analyses with the 
pharmacotherapy recommended in relevant guidelines for asthma (1), COPD (2), 
and allergic rhinitis and asthma (19), we found that they have clinical relevance. 
According to Global Initiative for Asthma (GINA), in a stepwise approach, if the 
response to the treatment is suboptimal, it is recommended to intensify the 
treatment, either by increasing the dose of currently used ICS and adding another 
controller medication, such as LABA, LTRA, and xanthines. On the other hand, 


















with nCS with either anti-H1 or LTRA for seasonal allergic rhinitis. Cluster 6 and 8, 
are profiles that closely resemble the GINA and ARIA recommendations for allergic 
asthma and rhinitis. 
Guidelines advise different COPD initial treatments depending on the severity of 
symptoms, exacerbations, and airflow limitation (2). It consists of a bronchodilator, 
either SABA or SAMA or LABA or LAMA and LABA or LAMA; and, if the symptoms 
persist, both LABA+LAMA or ICS+LABA. For more severe cases the recommended 
initial therapy is LAMA+LAMA or, in patients with a history suggestive of asthma-
COPD overlap or based on eosinophilic counts, ICS+LABA. The higher level of 
pharmacological care corresponds to triple therapy with LAMA+LABA+ICS or add-on 
of phosphodiesterase-4 inhibitor or a macrolide. Clusters 1 and 9 are profiles 
matching GOLD recommendations for COPD management. 
COPD therapeutic options have similarities with asthma treatment (Figure 3). The 
higher level of asthma care corresponds to treatment with a high dose of ICS+LABA 
and the add-on LAMA, IgE, a low dose of OCS or biological therapy(1). The GINA 
recommendations for treating patients with features of both asthma and COPD is 
ICS in a low or moderate dose and add-on treatment with LABA and/or LAMA. 
Clusters 2,4,5 and 7 are mixed profiles corresponding to medication for possible 
asthma or ACO. 
Until 2019, GINA recommended the use of SABA as the first line of asthma 
treatment (20). The recently published guide for asthma management by the GINA 
network, recommends that ICS should be used whenever SABA is used, and ICS 
combined with formoterol may be used in low dose as a reliever option (Figure 3) (1). 
Cluster 3 describes a profile corresponding to rescue medication for asthma and 
COPD; clusters 10 (exclusively prescribed by GPs) and 11 (mostly prescribed by 
specialties not related to respiratory diseases) are profiles for exacerbations and 
infection treatment. This indicates that in some clinical visits, patients on PRT only 
receive a prescription for infections and exacerbations and that the use of some of 
these medications may be related to other comorbidities. 
Studies that use prescription claims as proxies for diagnosis of asthma and COPD, 
based on a priori established algorithms, are controversial. Weidinger et al. used a 
representative sample of patients registered in primary healthcare units in Sweden to 


















medication for asthma and COPD (SABA, LABA, ICS, and fixed combinations of 
ICS+LABA) with the proportion of patients with a formal diagnosis for asthma or 
COPD(5). These results indicate that the use of prescriptions as a proxy for the 
diagnosis may not be accurate. However, another study on Dutch children 
diagnosed with atopic diseases reported that having two or more prescriptions for 
asthma, including ICS can be a reliable proxy for asthma (6). A systematic review of 
studies on the classification of asthma severity using claims data stated that no best 
theory-driven algorithm has been established so far (7). 
On the other hand, unsupervised methods, not based on a priori assumptions, bring 
new insight into the identification of patterns clinically relevant and with several 
applications. Slobbe et al. have shown that unsupervised methods applied to 
medication claims, may be used to predict the prevalence of six diseases, including 
asthma and COPD (21). Another study used clustering methods to establish and 
different profiles of patients based on airflow limitation and explore its characteristics, 
namely in terms of medication prescribed in each cluster of adult patients with mild-
to-moderate airflow limitation from the Korean National Health and Nutrition 
Examination Survey (16). Clustering methods have also been used to explore 
adherence barriers among respiratory patients, towards personalized care. A study 
using clusters based on adherence to inhalers in COPD patients, shown that certain 
demographic and clinical measurements, including lung function, cough and 
cognitive impairment, were determinants for different profiles of adherence (22). To 
the best of our knowledge, there are no studies using unsupervised methods with 
similar methodology and variable to support our results. 
This was the first analysis of the patterns of respiratory medication in the official 
Portuguese prescription database. Nevertheless, the present study has several 
limitations. The main limitation is related to the lack of information regarding 
treatment indication and duration of the treatment. Although we obtained prescription 
patterns with clinical relevance for asthma and COPD identification, having the 
diagnosis would allow the validation of the clustering method. Moreover, adding the 
indication could raise evidence on the medications commonly used for different 
indications and also used as off-label in the real-world. The duration of the treatment 
is also important for patient profiling, especially for exacerbation markers such as 

















interpretation of derived classes as being a true set of clinically meaningful 
subgroups (9). Finally, despite the large size of the analysed sample, it may not be 
representative of the Portuguese patients’ population, because we were not able to 
analyse the complete dataset of the BDNP.  
The clusters encountered in this study may be useful to explore primary adherence 
differences between patterns of prescriptions and also to compare with OTC 
patterns. To address the goals of management of chronic respiratory diseases, 
besides giving the appropriate prescription for each condition, factors such as 
adherence to the treatment and use of over-the-counter medication need to be 
optimized. RWD has contributed to a better understanding of primary nonadherence 
(23,24) and to raise awareness on the use of OTC medication for relievers of asthma 
symptoms (25). However, OTC uses of medication are not registered on the BDNP 
database and to the best of our knowledge, there is no data available on OTC 
medication for respiratory diseases in Portugal. In the future, studies on primary 
adherence, and also on OTC medication may uncover important barriers to 
adequate management of disease in the Portuguese population.  
 
Conclusion 
This study was based on prescription claims and revealed 11 prescription patterns 
for respiratory medication. These patterns could be grouped into four profiles; 
medication for possibly 1) Allergic Rhinitis and Asthma, 2) Asthma or ACO, 3) 
COPD, and 4) infection, exacerbation and relievers of symptoms medication and 
according to the prescribers’ specialties. This profiling is the first step to understand 
the Portuguese reality on the prescribing of respiratory medication. 
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Table 1: Frequency of prescribed packages of medication for respiratory diseases and exacerbations. 
Medication classes 
Packages 
n = 312 527 
n % 
Maintenance   
ICS + LABA 37 007 11.8 
LTRA 21 085   6.7 
LAMA alone 15 897   5.1 
LABA alone 10 738   3.4 
ICS alone 10 368   3.3 
LABA + LAMA 8 051   2.6 
Relievers   
SABA alone 8 730   2.8 
SAMA alone 5 639   1.8 
SABA + SAMA 303   0.1 
Exacerbation/infection markers   
Antibiotics 55 810 17.9 
OCS 27 399   8.8 
Other   
H1-antihistamines (systemic) 73 391 23.5 
Expectorant (systemic) 24 857   8.0 
Xanthine 8 475   2.7 
Cough suppressant (systemic) 4 691   1.5 
Cough suppressant with expectorant (systemic) 81   0.0 
Anti Immunoglobulin E 5   0.0 
ICS: inhaled corticosteroids; LABA: long-acting beta2 agonists; LTRA: leukotriene receptors antagonists; LAMA: 
long‑acting muscarinic antagonist; SABA: short-acting beta 2 agonist; SAMA: Short-acting muscarinic-antagonist; 












































  (9,5%) (6,6%) (8,3%) (6,0%) (13,1%) (7,6%) (12,0%) (5,8%) (6,7%) (14,2%) (10,3%) 
Age, med 68 74 63 66 75 68 63 70 44 72 63 66 
P25-P75 52-78 64-82 47-76 48-79 65-82 52-78 47-74 58-80 30-59 63-80 50-78 49-77 
Region             
South 45.4 8.7 7.7 8.3 6.0 10.2 6.7 12.4 7.6 6.7 14.0 11.6 
 44.9-45.9 8.3-9.1 7.4-8.1 7.9-8.7 5.7-6.4 9.8-10.6 6.4.-7.1 11.9-12.9 7.2-8.0 6.4-7.1 13.5-14.5 11.1-12.0 
North 32.4 11.0 5.6 9.2 4.1 15.3 7.6 12.6 4.4 6.6 14.2 9.5 
 31.9-32.8 10.4-11.5 5.2-6.0 8.7-9.7 3.8-4.5 14.7-15.9 7.1-8.0 12.0-13.1 4.1-4.8 6.2-7.0 13.6-14.8 9.0-10.0 
Centre 22.2 8.8 5.5 6.8 8.7 15.9 9.5 10.2 4.1 6.7 14.6 9.1 
 21.8-22.6 8.3-9.5 5.1-6.0 6.3-7.4 8.2-9.3 15.2-16.7 8.9-10.1 9.6-10.9 3.7-4.5 6.2-7.2 13.8-15.3 8.5-9.7 
Healthcare unit             
Primary care 48.3 11.0 0.3 7.8 5.7 22.7 12.4 14.6 0.0 6.5 19.3 0.1 
 47.8-48.8 10.6-11.5 0.3-0.4 7.5-8.2 5.4-6.1 22.1-23.3 11.9-12.9 14.1-15.1 0.0-0.0 6.2-6.9 18.7-19.9 0.0-0.2 
Secondary care 21.7 8.3 14.1 10.7 6.9 0.9 0.3 10.1 10.0 8.9 6.0 23.8 
 21.3-22.1 7.7-8.9 13.4-14.9 10.1-11.4 6.4-7.5 0.7-1.1 0.2-0.5 9.4-10.7 9.4-10.6 8.3-9.5 5.5-6.6 22.9-24.7 
Other 30.0 7.9 11.1 7.2 5.9 6.8 5.3 9.3 12.0 5.3 12.1 17.1 
 39.6-30.4 7.4-8.4 10.5-11.7 6.8-7.7 5.5-6.3 6.4-7.3 4.9-5.7 8.8-9.8 11.4-12.6 4.9-5.7 11.5-12.7 16.4-17.7 
Healthcare provider             
Public 69.7 10.1 4.6 8.7 6.1 15.8 8.6 13.1 3.1 7.3 15.1 7.5 
 69.2-70.1 9.8-10.5 4.4-4.9 8.4-9.1 5.8-6.3 15.4-16.2 8.2-8.9 12.7-13.5 2.9-3.3 7.0-7.6 15.7-15.5 7.2-7.8 
Private 30.3 7.9 11.0 7.2 5.9 7.0 5.4 9.4 11.9 5.3 12.2 16.9 




















Table S 1: Distribution of medication types and prescriber specialities by prescription clusters, determined by 2 
step cluster analysis. 
Clusters 1 2 3 4 5 6 7 8 9 10 11 
Medication type, %           
ICS + LABA 37.1 100.0 32.0 57.8 100.0 25.3 1.9 36.4 0.0 0.0 0.0 
LTRA 2.8 11.7 11.2 26.8 0.0 100.0 7.5 75.1 4.7 0.0 0.0 
ICS 0.0 0.0 20.3 1.3 0.0 0.0 54.8 0.9 14.9 0.0 0.0 
LABA 0.0 0.0 3.7 1.0 0.0 0.0 74.2 0.0 2.0 0.0 0.0 
SABA 0.0 0.0 71.2 15.9 0.0 0.0 2.9 0.0 3.4 0.0 0.0 
LAMA 100.0 0.0 5.2 36.7 0.0 0.0 16.7 0.0 0.9 0.0 0.0 
LABA + LAMA 0.0 0.0 1.1 6.1 0.0 0.0 0.0 0.0 100.0 0.0 0.0 
Xanthine 0.0 0.0 2.7 75.7 0.0 0.0 6.8 0.0 8.7 0.0 0.0 
SAMA 0.0 0.0 40.6 4.1 0.0 1.4 1.7 0.1 1.4 0.0 0.0 
SABA + SAMA 0.0 0.0 1.9 0.5 0.0 0.0 0.1 0.0 0.2 0.0 0.5 
Antibiotics 6.4 12.1 16.7 0.0 8.1 8.3 6.8 9.3 10.8 46.3 49.4 
OCS 3.7 8.4 10.1 9.4 2.3 2.0 3.4 7.7 5.2 12.1 25.1 
AntiH1 5.8 17.8 17.0 13.0 9.8 26.0 10.2 52.3 6.3 48.3 34.9 




6.1 9.0 10.3 8.0 5.7 5.0 5.0 4.0 10.5 31.5 21.6 
Prescriber specialty, %           
General 
practitioners 
66.3 0.0 58.5 60.5 100.0 100.0 67.3 0.0 56.4 100.0 0.0 
Pulmonologists 15.3 52.7 11.9 20.1 0.0 0.0 13.2 6.3 27.4 0.0 13.2 
Allergists 1.0 0.0 4.1 4.6 0.0 0.0 1.8 55.2 0.3 0.0 0.0 
Internist 7.0 13.0 10.3 6.4 0.0 0.0 5.9 6.2 6.7 0.0 23.0 





















Figure 1: Flowchart of patients and prescriptions (adapted from Sá-Sousa et al. (17). 
Figure 2: Frequency of each prescription cluster (%) determined by 2 step cluster analysis) and distribution of 
medication types, prescribers’ specialities and age of the patients in each cluster. The distribution of additional 
medication, not included in the model, is presented in shadow.  
Figure 3: Medication used in asthma management and common medication with COPD. 
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